HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 04, April 2019 – Career development for researchers       » CRISPR not as precise as thought       » Insomnia spreads among young Chinese       » Chinese HEV vaccine begin clinical trial in U.S       » Eating mushrooms may reduce risk of cognitive decline       » Green tea cuts obesity in mice      
INSIDE INDUSTRY
Australian Government to invest AU$200 million for cancer medicines
Almost 2000 people with leukaemia, advanced kidney cancer, bladder cancer and liver cancer will have affordable access to new treatment options, paying as little as AU$6.50 a script.

The Liberal National Government is investing more than AU$200 million to list four new breakthrough cancer treatments on the Pharmaceutical Benefits Scheme (PBS), saving patients up to a quarter of a million dollars a year.

Almost 1,800 eligible patients with leukaemia, advanced kidney cancer, bladder cancer and liver cancer will have new and innovative treatment options that have the potential to save and extend the lives of thousands of Australians and pay a little as AU$6.50 a script.

The new PBS cancer listings from 1 March 2019 include Venclexta (venetoclax) for relapsed or refractory chronic lymphocytic leukaemia, combination therapy Opdivo (nivolumab) and Yervoy (ipilimumab) for stage IV clear cell variant renal cell carcinoma, Keytruda (pembrolizumab) for locally advanced or metastatic urothelial cancer, and Lenvima (lenvatinib) for advanced hepatocellular carcinoma.

Since 2013, the Australian Government has more than 2,000 new or amended items on the PBS. This represents an average of around 30 listings per month—or one each day— at an overall cost of around AU$10.6 billion.

Click here for the complete issue.

NEWS CRUNCH  
news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy